CAPR Capricor Therapeutics Inc
Company Analysis
Latest News
Capricor Surges 24% on Fresh Duchenne Data, but Can Extension Results Overcome a 9-3 FDA Panel Rejection?
Shares of Capricor Therapeutics jumped +23.8% to $10.61 after new long-term clinical data showed that patients with Duchenne muscular dystrophy (DMD) — a...
🟢 Capricor Therapeutics is trading 23.1% up today after HOPE-3 extension data showed slower upper-limb decline
Capricor Therapeutics is trading 23.1% higher at $10.55 after HOPE-3 extension findings reported slower upper-limb and elbow-function decline among patients...
🟢 Capricor Therapeutics is trading 23.8% up in pre-market after HOPE-3 data showed slower upper-limb decline
Capricor Therapeutics is trading at $10.61, up +23.80%, after reports of HOPE-3 extension findings showing slower upper-limb and elbow-function decline among...
🟢 Capricor Therapeutics is trading 10.3% up in after-hours trading, with no clear catalyst identified
Capricor Therapeutics is trading at $9.45, up 10.27% after hours, with no clear company-specific catalyst identified. - The company is scheduled to present...
🟢 Capricor Therapeutics is trading 8% up in after-hours trading with no clear company-specific catalyst identified
Capricor Therapeutics is trading at $9.24, up 7.82%, in after-hours trading, with no clear company-specific catalyst identified for the September 29 rise. -...
🟢 Capricor Therapeutics is trading 5% up today
Capricor Therapeutics is trading 5.14% higher at $8.79, with no clear company-specific catalyst identified. - Broader U.S. markets were lower on September 28,...
🔴 Capricor Therapeutics is trading 6% down today as broad-market risk aversion likely weighs
Capricor Therapeutics is trading 6% lower at $8.78, with broad-market risk aversion the likelier immediate pressure. - A September 23 securities-fraud lawsuit...
🟢 Capricor Therapeutics is trading 5% up today with no clear company-specific catalyst
Capricor Therapeutics is trading at $9.36 (+5.17%) with no clear company-specific catalyst identified for the September 22, 2026 gain. - Recent coverage...
Capricor Therapeutics Sued Over Deramiocel Risks, Following 64% Stock Crash
Law firms are urging investors to join a securities class action lawsuit against Capricor Therapeutics. The lead plaintiff filing deadline is September 28,...
🟢 Capricor Therapeutics is trading 12.15% up today as U.S. indexes and biotech gain
Capricor Therapeutics is trading 12.15% up at $9.60, moving alongside a broad September 17, 2026 risk-on rally. - Major U.S. indexes are higher, while biotech...
🟢 Capricor Therapeutics is trading 6.19% up today amid a broader market rebound
Capricor Therapeutics is trading 6.19% up now at $9.09, amid a broader market rebound. - The gain comes during a strong September 17, 2026, risk-on session,...
🟢 Capricor Therapeutics is trading 5% up today as Nasdaq rises
Capricor Therapeutics is trading 5% up at $9.00, apparently aligned with stronger growth-stock sentiment as the Nasdaq rises despite biotech weakness. - No...
🟢 Capricor Therapeutics is trading 6.8% up today
Capricor Therapeutics is trading at $8.94, up 6.76%, with no new company-specific announcement identified overnight explaining the September 14, 2026 move. -...
🟢 Capricor Therapeutics is trading 5% up in pre-market; no company-specific catalyst found overnight
Capricor Therapeutics is trading 5.02% up at $8.79 after closing at $8.37 on September 11, 2026; no new company-specific announcement explaining the move was...
🔴 Capricor Therapeutics is trading 5% down today amid broad market pressure from hotter producer inflation
Capricor Therapeutics is trading 5% down now at $8.21, with no new company announcement directly explaining the September 10 decline; broader markets are...
🔴 Capricor Therapeutics is trading 5.4% down today after a securities-fraud lawsuit alleges misleading Deramiocel data
Capricor Therapeutics is trading 5.43% down at $8.89 after a securities-fraud class-action lawsuit announcement on September 8, 2026. Broader markets are...
🔴 Capricor Therapeutics is trading 6.37% down today after a securities-class-action lead-plaintiff deadline announcement
Capricor Therapeutics is trading 6.37% down now at $9.26 after Robbins Geller announced a September 28, 2026 lead-plaintiff deadline for a securities class...
🟢 Capricor Therapeutics is trading 5% up today after Piper Sandler upgrade, target raised to $25
Capricor Therapeutics is trading 5.09% up now at $10.52 after Piper Sandler upgraded the shares to Overweight from Neutral and raised its price target to $25...
🟢 Capricor Therapeutics is trading 6.61% up today after Piper Sandler upgrade to Overweight
Capricor Therapeutics is trading 6.61% up now at $10.56 after Piper Sandler upgraded the stock to Overweight from Neutral and raised its price target to $25...
🟢 Capricor Therapeutics is trading 5.5% up today
Capricor Therapeutics is trading 5.53% up now at $10.12, but no new company-specific announcement clearly explains the August 31, 2026 move. - Recent...